Celgene Co. (CELG) Shares Sold by TrueNorth Inc.

TrueNorth Inc. reduced its stake in Celgene Co. (NASDAQ:CELG) by 7.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,132 shares of the biopharmaceutical company’s stock after selling 1,813 shares during the quarter. Celgene comprises 1.6% of TrueNorth Inc.’s holdings, making the stock its 12th largest position. TrueNorth Inc.’s holdings in Celgene were worth $3,519,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Capital Counsel LLC NY grew its position in shares of Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC grew its position in shares of Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares in the last quarter. Flagship Harbor Advisors LLC grew its position in shares of Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares in the last quarter. Savant Capital LLC grew its position in shares of Celgene by 0.9% during the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares in the last quarter. Finally, TCI Wealth Advisors Inc. grew its position in shares of Celgene by 0.9% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 26 shares in the last quarter. 79.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Co. (CELG) opened at $106.33 on Monday. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market cap of $83,720.00, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 0.84 and a beta of 1.77.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the business posted $1.58 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. equities research analysts expect that Celgene Co. will post 6.68 EPS for the current fiscal year.

A number of brokerages have issued reports on CELG. Citigroup restated a “hold” rating on shares of Celgene in a research report on Friday. Oppenheimer set a $166.00 price target on shares of Celgene and gave the stock a “buy” rating in a research report on Friday. Credit Suisse Group set a $123.00 price target on shares of Celgene and gave the stock a “buy” rating in a research report on Friday. Stifel Nicolaus reduced their price target on shares of Celgene from $149.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene presently has a consensus rating of “Buy” and an average price target of $135.43.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/25/celgene-co-celg-shares-sold-by-truenorth-inc.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit